EMPRISE real-world study results

Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019  EMPRISE is an ongoing real-world evidence study in 35,000 people with type 2 diabetes in the US, comparing empagliflozin with DPP-4 inhibitors; initial results based on the first two years of the study were presented at AMCP 2019 and ACC.191,2Initial results presented at AMCP 2019 showed empagliflozin was associated with reductions in all-cause hospitalisations compared with DPP-4 inhibitors, and significantly fewer recurrent emergency department visits and physician office visits1Initial results presented at ACC.19 showed empagliflozin was associated with a reduction in hospitalisation for heart failure or all-cause mortality, and was not associated with an increased risk of bone fracture or lower leg amputation compared to DPP-4 inhibitors2
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news

Related Links:

This study evaluated whether A1C influences a composite outcome of either HF hospitalization or CV death differently along the spectrum of LVEF.Methods and resultsWe assessed the relationships of baseline A1C and LVEF with a composite outcome of either CV death or HF hospitalization in the 4091 patients with type 2 diabetes and a recent acute coronary syndrome enrolled in the ELIXA trial who had available LVEF. We assessed for interaction between A1C and LVEF as continuous variables with respect to this outcome. During a median follow ‐up of 25.7 months, 343 patients (8.4%) had HF hospitalization or died of CV ca...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
Left ventricular ejection fraction (LVEF) trajectories and functional recovery with current heart failure (HF) management is increasingly recognized. Type 2 diabetes mellitus (T2D) leads to a worse prognosis i...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Recent clinical trials have demonstrated significant reductions in heart failure hospitalization and cardiovascular death with sodium-glucose cotransport protein 2 inhibitors in patients with or without type 2 diabetes mellitus.1-3 The mechanism of cardiovascular benefit with sodium-glucose transport coprotein 2 inhibitors was investigated in the EMPA-HEART CardioLink-6 trial, a double-blind, placebo-controlled clinical trial that randomized patients with type 2 diabetes and stable coronary artery disease to empagliflozin 10  mg once daily (n = 49) or placebo (n = 48).
Source: Journal of the American Society of Echocardiography - Category: Cardiology Authors: Tags: Letters to the Editor Source Type: research
Abstract Type 2 diabetes mellitus (T2DM) is a rapidly evolving global health issue associated with a markedly increased risk of cardiovascular (CV) morbidity and mortality. The hyperglycaemic milieu contributes to the development of CV complications via several pathological pathways, leading to increased arterial stiffness (AS), that can be considered as a predictor of CV events in patients with diabetes. The measurement of AS is increasingly used for the clinical assessment of patients. Several methodologies were used in large population studies to assess AS; the most commonly used is the pulse wave velocity (PWV...
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research
Authors: Guthrie R Abstract Review of:Rosenstock J, Perkovic V, Johansen, OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69-79.McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation. 2019;139:351-361.These two papers describe the findings from the CARMELINA trial (Cardiovascular and Renal Microvascular Outco...
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research
Abstract Sodium-glucose cotransporter 2 inhibitors reduce the risk of serious heart failure and adverse renal events, but the mechanisms that underlie this benefit are not understood. Treatment with SGLT2 inhibitors is distinguished by two intriguing features - ketogenesis and erythrocytosis. Both reflect the induction of a fasting-like and hypoxia-like transcriptional paradigm that is capable of restoring and maintaining cellular homeostasis and survival. In the face of perceived nutrient and oxygen deprivation, cells activate low-energy sensors, which include sirtuin-1 (SIRT1), adenosine monophosphate-activated ...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
You may have already heard the term “insulin resistance,” as it has been widely discussed by doctors and the media. But did you know that you can reduce or reverse it in the vast majority of people? Insulin resistance, i.e., the inability of the body’s cells, especially liver, muscle, and brain, to respond to insulin and allow blood sugar to enter cells, drives numerous abnormal health conditions including type 2 diabetes, hypertension, coronary heart disease, fatty liver, Alzheimer’s dementia, and cancer. It is therefore a driving force behind so many modern and common chronic health conditions. Yo...
Source: Wheat Belly Blog - Category: Cardiology Authors: Tags: Open can belly fat can insulin resistance be reversed lose weight reduce belly fat reverse inflammation visceral fat wheat belly Source Type: blogs
AbstractMetformin is considered a safe anti-hyperglycemic drug for patients with type 2 diabetes (T2D); however, information on its impact on heart failure –related outcomes remains inconclusive. The current systematic review explored evidence from randomized clinical trials (RCTs) reporting on the impact of metformin in modulating heart failure–related markers in patients with or without T2D. Electronic databases such as MEDLINE, Cochrane Library, and EMBASE were searched for eligible studies. Included studies were those assessing the use of metformin as an intervention, and also containing the comparison grou...
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
PMID: 32149774 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
More News: Cardiology | Diabetes | Diabetes Type 2 | Emergency Medicine | Empagliflozin | Endocrinology | Heart | Heart Failure | Jardiance | Orthopaedics | Research | Study